-

12:10:14 AM

MOLN Stock News

MOLN - Molecular Partners AG

05/25/23 5:01 PM

Nasdaq : MOLN

conferencesclinical triallow float

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combination

RHEA-AI

neutral

05/16/23 4:00 PM

Nasdaq : MOLN

conferenceslow float

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Patrick Amstuts, Chief

RHEA-AI

neutral

05/11/23 4:00 PM

Nasdaq : MOLN

earningslow float

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort (Q3W, 10mg/kg) now enrolling; clinical update at ASCO Radio DARPin Therapy (RDT): Presented preclinical

RHEA-AI

neutral

04/14/23 1:00 AM

Nasdaq : MOLN

conferencesclinical triallow float

Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR

Targeted radionuclide delivery platform strengthened by new safety and mechanistic data Data includes review of high tumor penetration potential of DARPins and reduced kidney accumulation via DARPin engineering New findings will be shared on April 18, 2023, at the American Association for Cancer

RHEA-AI

neutral

04/04/23 11:44 AM

Nasdaq : MOLN

low float

Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the shareholders of the

RHEA-AI

neutral

03/13/23 9:30 AM

Nasdaq : MOLN

low float

Molecular Partners Publishes Invitation to Annual General Meeting 2023

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual

RHEA-AI

neutral

03/09/23 4:00 PM

Nasdaq : MOLN

low float

Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022

Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64th

RHEA-AI

neutral

03/02/23 4:00 PM

Nasdaq : MOLN

low float

Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its

RHEA-AI

neutral

02/28/23 1:15 AM

Nasdaq : MOLN

clinical triallow float

Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform

Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues Data reveal engineering approach to significantly reduce kidney accumulation of DARPin-based radiotherapeutic candidates to potentially expand

RHEA-AI

neutral

02/10/23 1:00 AM

Nasdaq : MOLN

conferenceslow float

Molecular Partners to Present at SVB Leerink Global Healthcare Conference

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive

RHEA-AI

neutral

1 2 3 4 5 6 Next